December 2, 2024|Access to Medicines, Health JusticeOn World AIDS Day, Activist Coalition Demands Accelerated Access to Revolutionary HIV PreventionPRESS STATEMENT For Immediate Release: December 2, 2024 Activist Coalition Demands Accelerated Access to Revolutionary HIV Prevention Calls on Governments in the Global South to Break Trade and Intellectual Property Barriers and Take on Gilead’s Power Countdown to access campaign…
October 30, 2024|Access to MedicinesBavarian Nordic Mpox Shot Now Second-Most Expensive Vaccine UNICEF DistributesHealth Groups Urge Bavarian Nordic to Cut High Price of Mpox Vaccine, Quadruple Supply Under Existing UNICEF agreement. WASHINGTON D.C. — At $65 per dose, Bavarian Nordic’s mpox vaccine, Jynneos (MVA-BN), is the second-most expensive vaccine that UNICEF distributes, according…
October 2, 2024|Access to MedicinesGilead’s Access Strategy for Lenacapavir Will Unnecessarily Prolong the HIV Pandemic Activists Call for Affordable Access for all Low- and Middle-Income CountriesActivists reacted to Gilead’s announcement of plans to license lenacapavir, a long acting injectable for HIV prevention and treatment, to 6 generic companies that would supply 120 low- and middle-income countries. Lenacapavir has been shown to be highly effective in…
July 23, 2024|Access to MedicinesActivists at AIDS2024 Demand: Break Gilead’s Lenacapavir Monopoly Gilead’s Price 100,000% Higher than Target Generic Price for 100% Effective Prevention Shot(Munich) Today at AIDS 2024, a coalition of activists called for immediate global action to break Gilead’s monopoly on lenacapavir, in response to new data showing that generic lenacapavir can be produced at a price one thousand times less than…
February 6, 2024|Access to MedicinesStatement from Naïké Ledan, Health GAP Director of International Policy & Advocacy, on Colombia’s Historic Compulsory License for DolutegravirStatement from Naïké Ledan, Health GAP Director of International Policy & Advocacy, on Colombia’s Historic Compulsory License for Dolutegravir "Dolutegravir (DTG) is a lifesaving HIV treatment that can improve and extend the lives of people with HIV. DTG-based regimens are…
October 17, 2023|Access to MedicinesNew Analysis Reveals Shocking Extent of Unmet Need for Paxlovid in LMICs During COVID-19 EmergencyWashington, D.C. – In an analysis released today, Public Citizen and the Health Global Access Project (Health GAP) found that the number of people with high risk COVID-19 infections in low and middle income countries (LMICs) exceeded procured supply of…
December 1, 2022|Access to Medicines, COVID-19, Funding the Fight, Health Justice, Transparency & AccountabilityFORGOTTEN BUT NOT GONE: On World AIDS Day, People with HIV, Long COVID and ME/CFS Protest Biden’s Pandemics Neglect, Urge Funding from Congress in Demonstration Outside the White HouseDecember 1, 2022 FOR IMMEDIATE RELEASE In an unprecedented on-site and virtual World AIDS Day protest, people with HIV united with chronically ill and disabled people with Long COVID, myalgic encephalomyelitis (ME/CFS), and others, in a rally today outside the…
July 28, 2022|Access to Medicines, Funding the Fight, Health JusticeHealth GAP Statement regarding ViiV – MPP Voluntary Licensing Agreement for CAB-LAFOR IMMEDIATE RELEASE July 28, 2022 Health GAP Statement regarding ViiV - MPP Voluntary Licensing Agreement for CAB-LA “Just four months ago, ViiV announced it would not pursue voluntary licensing for CAB-LA to allow generic manufacturing and accessible pricing for…
June 17, 2022|Access to Medicines, COVID-19Statement from Asia Russell, Health GAP Executive Director, on the Failure of the WTO’s MC12 to Deliver a TRIPS Waiver for COVID-19 Vaccines, Treatments, and Tests“The World Trade Organization’s 12th Ministerial Conference (MC12) was a dismal failure for the 85% of people in low-income countries that have not had a single dose of COVID-19 vaccine, for the billions of people worldwide without access to COVID-19…
May 4, 2022|Access to MedicinesCampaigners protest GSK for pricing game-changing HIV prevention medication 100 times more expensive than gold, blocking global accessCampaigners unfurl banner outside GlaxoSmithKline Annual General Meeting demanding subsidiary ViiV Healthcare sell new injectable at a price comparable to generic oral prevention pills, and immediately commit to sharing technology with generic manufacturers As GSK shareholders gather in person at…
